<?xml version="1.0" encoding="UTF-8"?>
<p id="par0270">Despite promising primary data, when it comes to studies regarding optimal timing and IL-6 threshold of Tocilizumab administration during the course of COVID-19, information is still lacking from larger, controlled, long-term studies. Moreover, IL-6 monitoring might be an obstacle in some institutions, and its adverse effects bacterial infection susceptibility, neutropenia and thrombocytopenia should be considered when a clinical decision is to be made. Two clinical trials are ongoing right now which might provide further needed information [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0190" ref-type="bibr">38</xref>].
</p>
